Literature DB >> 12807506

The relation between two polymorphisms in the glucocorticoid receptor gene and body mass index, blood pressure and cholesterol in obese patients.

Anna Maria Di Blasio1, Elisabeth F C van Rossum, Sabrina Maestrini, Maria Elisa Berselli, Mariantonella Tagliaferri, Francesca Podestà, Jan W Koper, Antonio Liuzzi, Steven W J Lamberts.   

Abstract

OBJECTIVE: We have recently reported that, in healthy elderly Dutch individuals, a N363S polymorphism in the glucocorticoid receptor (GR) gene is associated with higher sensitivity to low-dose dexamethasone (0.25 mg), evaluated as both cortisol suppression and insulin response, and with an increased body mass index (BMI). In the present study we investigated the role of the N363S polymorphism, and a BclI restriction site polymorphism in a group of Italian patients with severe obesity.
DESIGN: Two hundred and seventy-nine patients (mean BMI 45.9 +/- 0.9 kg/m2) were genotyped using both PCR-restriction fragment length polymorphism analysis and Taqman Sequence Detection System. Determination of several metabolic and antropometric parameters was also performed in order to correlate them to the genotype.
RESULTS: In this group of obese patients, 13 subjects (eight female, five males) were heterozygous for the N363S variant (allelic frequency 2.3%) and had significantly higher BMI (P < 0.04), resting energy expenditure (P < 0.03) and food intake (P < 0.01) when compared to wild-type homozygotes. When the data were analysed according to sex, female heterozygotes for the N363S allele had significantly higher BMI (P = 0.04), resting energy expenditure (P = 0.03) and food intake (P = 0.008) than obese women with the wild-type 363 GR gene. Male carriers of this variant also had higher values for these variables although the differences did not reach statistical significance. A case-control study with homozygous wild-type obese subjects which were age-, sex- and BMI-matched, revealed no difference in resting energy expenditure and food intake. The allele frequency of the BclI variant was 27% (89 females and 41 males out of 269 subjects). No differences in anthropometric and metabolic parameters were found between subjects heterozygous or homozygous for this variant GR in this obese population. However, when we studied the effect of the presence of the BclI polymorphism and the N363S variant in the same individual, we found that the subjects who carried both polymorphisms had a tendency towards higher systolic and diastolic blood pressure and significantly higher total and LDL-cholesterol levels (P = 0.005 and P = 0.05, respectively). DISCUSSION: Taking the results of this study and those obtained in the Dutch population, we speculate that heterozygous carriers of the N363S variant who develop obesity, may become even more obese, possibly because they have a hypersensitive insulin response and thus, via activation of lipogenesis, store fat more efficiently. Furthermore, these data suggest that N363S carriers who carry the BclI polymorphism as well, tend to have a slightly unfavourable cardiovascular profile.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12807506     DOI: 10.1046/j.1365-2265.2003.01798.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  36 in total

Review 1.  Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 in obesity.

Authors:  Deborah J Wake; Brian R Walker
Journal:  Endocrine       Date:  2006-02       Impact factor: 3.633

2.  Association between BclI polymorphism in the NR3C1 gene and in vitro individual variations in lymphocyte responses to methylprednisolone.

Authors:  Eva Cuzzoni; Sara De Iudicibus; Fiora Bartoli; Alessandro Ventura; Giuliana Decorti
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

Review 3.  Corticosteroid receptor genetic polymorphisms and stress responsivity.

Authors:  Roel DeRijk; E Ronald de Kloet
Journal:  Endocrine       Date:  2005-12       Impact factor: 3.633

4.  Molecular evidence for a link between the N363S glucocorticoid receptor polymorphism and altered gene expression.

Authors:  Christine M Jewell; John A Cidlowski
Journal:  J Clin Endocrinol Metab       Date:  2007-05-29       Impact factor: 5.958

5.  Glutathione-S-transferase-P1 I105V polymorphism and response to antenatal betamethasone in the prevention of respiratory distress syndrome.

Authors:  Chiara Oretti; Sara Marino; Fabio Mosca; Maria Rosa Colnaghi; Sara De Iudicibus; Ilenia Drigo; Gabriele Stocco; Fiora Bartoli; Giuliana Decorti; Sergio Demarini
Journal:  Eur J Clin Pharmacol       Date:  2009-01-29       Impact factor: 2.953

Review 6.  Tissue-specific glucocorticoid action: a family affair.

Authors:  Katherine L Gross; John A Cidlowski
Journal:  Trends Endocrinol Metab       Date:  2008-09-19       Impact factor: 12.015

Review 7.  The Role of Aldosterone in Obesity-Related Hypertension.

Authors:  Wakako Kawarazaki; Toshiro Fujita
Journal:  Am J Hypertens       Date:  2016-02-28       Impact factor: 2.689

Review 8.  The role of glucocorticoids and progestins in inflammatory, autoimmune, and infectious disease.

Authors:  A Sasha Tait; Cherie L Butts; Esther M Sternberg
Journal:  J Leukoc Biol       Date:  2008-07-29       Impact factor: 4.962

9.  Glucocorticoid receptor haploinsufficiency causes hypertension and attenuates hypothalamic-pituitary-adrenal axis and blood pressure adaptions to high-fat diet.

Authors:  Z Michailidou; R N Carter; E Marshall; H G Sutherland; D G Brownstein; E Owen; K Cockett; V Kelly; L Ramage; E A S Al-Dujaili; M Ross; I Maraki; K Newton; M C Holmes; J R Seckl; N M Morton; C J Kenyon; K E Chapman
Journal:  FASEB J       Date:  2008-08-12       Impact factor: 5.191

10.  The variant N363S of glucocorticoid receptor in steroid-induced ocular hypertension in Hungarian patients treated with photorefractive keratectomy.

Authors:  Viktória Szabó; Gábor Borgulya; Tamás Filkorn; Judit Majnik; Ilona Bányász; Zoltán Zsolt Nagy
Journal:  Mol Vis       Date:  2007-04-27       Impact factor: 2.367

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.